Latest News

New York / London May 28, 2018 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced that it will...

Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.

Tiziana announces that on 1 May 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note 11 to Rule 9.1 of the City Code on Takeovers and Mergers.

Tiziana announces an update regarding its Investigational New Drug application to the FDA to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.

Tiziana announces that on 25 April 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought American Depositary Shares each representing 10 ordinary shares of nominal value 3p each in the capital of the Company

80% of patients who completed treatment within the trial’s timeframe requested to continue treatment on compassionate use grounds